Authors: Knowling, M Browman, G Siu, L Khoo, K Cooke, A Tannock, I Klaassen, D Cripps, C Goss, G Matthews, S Clarke, R Seymour, L

Citation: M. Knowling et al., A National Cancer Institute of Canada Clinical Trials Group phase II studyof eniluracil (776C85) and oral 5-fluorouracil in patients with advanced squamous cell head and neck cancer, ANN ONCOL, 12(7), 2001, pp. 919-922

Authors: Stewart, DJ Goel, R Gertler, SZ Huan, S Tomiak, EM Yau, J Cripps, C Evans, WK

Citation: Dj. Stewart et al., Concurrent use of multiple low dose chemotherapy agents with differing mechanisms of action as a strategy vs passive resistance: A pilot study, INT J ONCOL, 15(4), 1999, pp. 693-699

Authors: Cripps, C Burnell, M Jolivet, J Batist, G Lofters, W Dancey, J Iglesias, J Fisher, B Eisenhauer, EA

Citation: C. Cripps et al., Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: An NCIC ClinicalTrials Group study, ANN ONCOL, 10(10), 1999, pp. 1175-1179

Authors: Warner, E Jensen, JL Cripps, C Khoo, KE Goel, R Kerr, IA Bjarnason, GA Fields, ALA Hrincu, A

Citation: E. Warner et al., Outpatient 5-fluorouracil, folinic acid and cisplatin in patients with advanced esophageal carcinoma, ACTA ONCOL, 38(2), 1999, pp. 255-259

Authors: Bjarnason, GA Cripps, C Goel, R Fine, S Oza, AM Skillings, JR Kerr, I Germond, CJ Moore, MJ Maroun, JA Franssen, E Dulude, H

Citation: Ga. Bjarnason et al., Phase I-II study of 5-fluorouracil, leucovorin, doxorubicin, methotrexate,and long-term oral etoposide (FLAME) in unresectable or metastatic gastriccancer, AM J CL ONC, 21(6), 1998, pp. 537-542